The INITIATE study shows an option for starting dose and titration for patients with type 2 diabetes who are starting insulin therapy with NovoLog® Mix 70/30.
Simple 1:1 unit conversion.
More flexible dosing.
Convert patients from human premix insulin (eg, Novolin® 70/30) to NovoLog® Mix 70/30 using a simple 1:1 unit conversion
The INITIATE Study: starting dose and titration
Results from a 28-week, randomized, multicenter, open-label, parallel-group, treat-to-target study with a 4-week metformin optimization period with or without thiazolidinediones. There were 233 insulin-naïve patients with type 2 diabetes who were randomized to either twice-daily NovoLog® Mix 70/30 before breakfast and dinner or to once-daily insulin glargine at bedtime. Primary endpoint was reduction in A1C values from baseline to end of study.1
66% of patients reached A1C goal <7% with twice-daily dosing of NovoLog® Mix 70/30 compared with 40% with once-daily glargine (P<0.001)1
In the INITIATE study, weekly dose adjustments were made for the first 12 weeks and biweekly adjustments thereafter to achieve target FPG (fasting plasma glucose) and predinner blood glucose of 80 to 110 mg/dL. Adjustments were based on self-measured plasma glucose (SMPG) readings (prebreakfast or predinner) from the previous 3 days. If 2 of the 3 readings were not within target, dose adjustment was based on the lowest reading. Predinner doses were titrated based on FPG values. Prebreakfast doses were titrated based on predinner SMPG values.1
Dosing of NovoLog® Mix 70/30 must be individualized.
Every minute counts
NovoLog® Mix 70/30 can be dosed within 15 minutes before or after starting a meal in adult patients with type 2 diabetes, compared with 30 minutes before a meal required by human premix insulin.2
Introduce patients to the features of the discreet, prefilled NovoLog® Mix 70/30 FlexPen®
Check your patients’ formulary coverage in just 2 steps